Hydrochloric Acid → N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide

HRID 336804

反応式

HRID 336804 の反応式
[NH2:1][C:2]1[CH:3]=[C:4]([S:8]([NH:11][C:12]2[C:21]([NH:22][C:23]3[CH:28]=[C:27]([O:29][CH3:30])[CH:26]=[C:25]([O:31][CH3:32])[CH:24]=3)=[N:20][C:19]3[C:14](=[CH:15][CH:16]=[CH:17][CH:18]=3)[N:13]=2)(=[O:10])=[O:9])[CH:5]=[CH:6][CH:7]=1.C(OC([N:40]1[CH2:43][CH:42]([C:44](O)=[O:45])[CH2:41]1)=O)(C)(C)C.CCN(C(C)C)C(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.Cl.O1CCOCC1>CC(N(C)C)=O>[CH3:30][O:29][C:27]1[CH:28]=[C:23]([NH:22][C:21]2[C:12]([NH:11][S:8]([C:4]3[CH:3]=[C:2]([NH:1][C:44]([CH:42]4[CH2:43][NH:40][CH2:41]4)=[O:45])[CH:7]=[CH:6][CH:5]=3)(=[O:9])=[O:10])=[N:13][C:14]3[C:19]([N:20]=2)=[CH:18][CH:17]=[CH:16][CH:15]=3)[CH:24]=[C:25]([O:31][CH3:32])[CH:26]=1

参加物

8

実験手順

Into a 20 mL vial was added 3-amino-N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)benzenesulfonamide (0.24 mmol, 1 equiv), prepared using procedures similar to those described in Example 15, DMA (5 mL) and 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (0.336 mmol, 1.4 equiv). Hunig's Base (0.792 mmol, 3.3 equiv) and HATU (0.288 mmol, 1.2 equiv) were added to the vial and the reaction mixture was then stirred at room temperature, overnight. Completion of the reaction was indicated by LCMS. The solvent was removed by rotary evaporation. The crude mixture was carried forward without further purification. The residue was suspended in 5 mL ethyl acetate and chilled in an ice bath. A solution of 4 N HCl in dioxane (3 mL, 5 equiv) was added with stirring. The reaction mixture was then stirred at room temperature overnight. The solid materials were collected by filtration, washed with ethylacetate then purified further by preparative reverse-phase HPLC (ammonium acetate/ACN). A Waters Fractionlynx preparative reverse-phase HPLC; equipped with a Waters SunFire Prep C18, OCD 5 μM, 30×70 mm column and running a 5-100% gradient with a binary solvent system of 25 mM ammonium acetate in water/acetonitrile; was used to carry out the purification. N-(3-(N-(3-(3,5-dimethoxy-phenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)azetidine-3-carboxamide was obtained (26 mg, 20%). 1H-NMR (400 MHz, d6-DMSO): 10.26 (s, 1H), 8.81 (s, 1H), 8.25 (t, 1H), 8.14 (s, 1H), 7.74 (d, 1H), 7.69 (d, 1H), 7.41-7.39 (m, 1H), 7.36 (d, 1H), 7.32 (d, 2H), 7.30-7.28 (dd, 1H), 7.14-7.11 (m, 2H), 6.14 (t, 1H), 4.09 (d, 4H), 3.78 (s, 6H); MS (EI) m/z C26H26N6O5S: 535.6 (MH+).

後処理

  1. customprepared
  2. customThe solvent was removed by rotary evaporation
  3. customThe crude mixture was carried forward without further purification
  4. temperaturechilled in an ice bath
  5. stirringwith stirring
  6. stirringThe reaction mixture was then stirred at room temperature overnight
  7. filtrationThe solid materials were collected by filtration
  8. washwashed with ethylacetate
  9. customthen purified further by preparative reverse-phase HPLC (ammonium acetate/ACN)
  10. customequipped with a Waters SunFire Prep C18, OCD 5 μM, 30×70 mm column
  11. customthe purification

出典と根拠

ORDレコード
ord-7e75f00efd1f46658cbb7a66fa6b040a
出典データセット
uspto-grants-2014_11
特許番号
US08889664B2

関連ノート

読み込み中…